A Cross-over Relative Bioavailability (RBA) Study of LY03005 vs Pristiq
Condition:   Major Depressive Disorder Interventions:   Drug: LY03005;   Drug: Pristiq Sponsor:   Luye Pharma Group Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2018 Category: Research Source Type: clinical trials

A Study of LY03005 vs Pristiq
Condition:   Major Depressive Disorder Interventions:   Drug: LY03005;   Drug: Pristiq Sponsor:   Luye Pharma Group Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2018 Category: Research Source Type: clinical trials

Switching From SSRI to Desvenlafaxine on Cognitive Functioning
Condition:   Major Depressive Disorder Intervention:   Drug: Desvenlafaxine Sponsors:   Corporacion Parc Tauli;   Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2018 Category: Research Source Type: clinical trials

A Cross-over Relative Bioavailability (RBA) Study of LY03005 vs Pristiq ®
Condition:   Major Depressive Disorder Interventions:   Drug: LY03005;   Drug: Pristiq Sponsor:   Luye Pharma Group Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2017 Category: Research Source Type: clinical trials

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq ®
Condition:   Major Depressive Disorder Interventions:   Drug: LY03005;   Drug: Pristiq Sponsor:   Luye Pharma Group Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2017 Category: Research Source Type: clinical trials

Pilot BA Study of New LY03005 vs Pristiq
Condition:   Major Depression Interventions:   Drug: LY03005;   Drug: Pristiq Sponsor:   Luye Pharma Group Ltd. Recruiting - verified December 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 2, 2016 Category: Research Source Type: clinical trials